Acute rejection of renal transplant

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

Heart transplant recipients with male donor-female recipient gender mismatch had significantly more treated acute rejections and were rehospitalized more days during the first post-operative year comp

Effect: decline; Group 3 mean rejections 4.7 vs Group 1 mean 2.8; Group 3 mean rehospitalization 39 days vs Group 1 mean 22 days

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year

The belatacept-sirolimus regimen with alemtuzumab induction successfully prevented clinical biopsy-proven acute rejection in all 20 live donor kidney transplant recipients within the first year, with

Effect: improvement; 0/20 clinical acute rejections in first year